leisure time -WSS

leisure time

author：focus 2025-09-02 22:03:33 - browse：654

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： CDC recommends RSV monoclonal antibody for infants

WSS

STAT Summit: The economic case for universal basic health care

ADCs take center stage as promising cancer treatments

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Roche drug slashes death risk in early

Roche acquires Telavant from Roivant, adding experimental IBD treatment

hotspot

leisure time

hotspot

In age of alternative facts, a scholarly course on calling out crap

How I helped Pfizer think through the ethics of Viagra

BioMarin wins approval for gene therapy to treat hemophilia A

J&J lung cancer data amount to new salvo against AstraZeneca

Virginia high school admissions case could be legal follow

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

The high cost of giving birth even with insurance

Readout LOUD podcast: Live from the 2023 STAT Summit

United colonoscopy coverage change 'may cost lives,' doctors say

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

hotspot

FDA scientists endorse Pfizer/BioNTech Covid

FDA approves Sage Therapeutics’ rapid

CDC recommends RSV monoclonal antibody for infants

Roivant's CEO is a star, but biotech's black hole persists

How AI can help patients find reliable information about doctors

Study links childhood stress with decline in older age

hotspot

leisure time

focus

focus